The results from this study demonstrate that there are high-risk osteoporosis patient cohorts where teriparatide use as a first-line agent is a cost-effective treatment option compared to ...
Teriparatide (recombinant) 250mcg/mL; soln for SC inj; contains m-cresol. Teriparatide stimulates new bone formation on trabecular and cortical (periosteal and/or endosteal) bone surfaces by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback